TFA Therapeutics (RAJAF) Revenue (2020 - 2023)

TFA Therapeutics has reported Revenue for 4 years, with the latest figure at $315502.0 in Q4 2023.

• On a quarterly basis, Revenue rose 3221.42% year-over-year to $315502.0 in Q4 2023; TTM through Dec 2023 was $467445.0, a N/A change from a year earlier, with the FY2025 full-year figure at $1.2 million, down 0.65% from the prior year.
• Revenue was $315502.0 for Q4 2023 at TFA Therapeutics, up from $9499.0 in the prior quarter.
• The five-year high for Revenue was $315502.0 in Q4 2023, with the low at $7724.0 in Q4 2021.
• Average Revenue over 4 years is $116861.2, with a median of $72109.5 recorded in 2020.
• The sharpest annual moves came in 2021 and 2023: Revenue plunged 94.27% in 2021, then surged 3221.42% in 2023.
• Over 4 years, Revenue stood at $134720.0 in 2020, then slumped by 94.27% to $7724.0 in 2021, then gained by 22.98% to $9499.0 in 2022, then soared by 3221.42% to $315502.0 in 2023.
• The last three Revenue figures came in at $315502.0 (Q4 2023), $9499.0 (Q4 2022), and $7724.0 (Q4 2021), per Business Quant data.